Please use this identifier to cite or link to this item: https://scholarbank.nus.edu.sg/handle/10635/225758
DC FieldValue
dc.titleDesigner Babies and the Law: A Legal Analysis of Human Germline Editing in Light of the UK’s Human Rights Obligations
dc.contributor.authorChua, Hui Min Hillary
dc.date.accessioned2022-05-19T02:22:56Z
dc.date.available2022-05-19T02:22:56Z
dc.date.issued2017-03-01
dc.identifier.citationChua, Hui Min Hillary (2017-03-01). Designer Babies and the Law: A Legal Analysis of Human Germline Editing in Light of the UK’s Human Rights Obligations. The King’s Student Law Review 8 (1) : 68-87. ScholarBank@NUS Repository.
dc.identifier.urihttps://scholarbank.nus.edu.sg/handle/10635/225758
dc.description.abstractIn light of the UK’s progressive embrace of new biotechnologies, and the recent scientific breakthrough of CRISPR/Cas-9 (a gene-editing technology), this paper investigates whether the UK could legalise the genetic editing of human embryos (intended for implantation and birth) in the near future, given its international human rights obligations. In particular, this paper examines the bans against human genome editing that are found in the Council of Europe’s Oviedo Convention and UNESCO’s Universal Declaration on the Human Genome and Human Rights. These bans reflect an existing European consensus against editing inheritable human genes (human germline editing). Therefore, this paper determines that the bans can be incorporated into the UK’s European Convention on Human Rights (ECHR) obligations, to bind the UK. Nevertheless, this paper suggests that once gene-editing technologies are perfected, European attitudes may shift to embrace human germline editing. However, distinctions would have to be made between germline editing for (i) the treatment of physical suffering; (ii) the enhancement of healthy individuals; and (iii) discrimination against disabled groups. Whilst the latter two uses of the technology are dangerously eugenic, therapeutic gene-editing within carefully-defined limits is ethically justifiable, and is likely to be permitted by ECHR law in the near future. Hence, this paper predicts that the UK can and will legalise germline therapy in the near future. In doing so, Article 2 of the ECHR (the right to life) will require the UK to determine what constitutes an acceptable level of risk before legalising the therapy, whilst Article 8 (the right to private and family life) would support the therapy’s legalisation, albeit for a narrow and carefully-decided list of genetic conditions.
dc.publisherThe King's Student Law Review
dc.sourceElements
dc.typeArticle
dc.date.updated2022-05-18T15:36:06Z
dc.contributor.departmentDEAN'S OFFICE (LAW)
dc.description.sourcetitleThe King’s Student Law Review
dc.description.volume8
dc.description.issue1
dc.description.page68-87
dc.published.statePublished
Appears in Collections:Elements
Staff Publications

Show simple item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
8.1.5-Hillary-Chua-68-87.pdf545.62 kBAdobe PDF

OPEN

PublishedView/Download

Google ScholarTM

Check


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.